11:46 AM EST - BriaCell Therapeutics Corp. : Announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.03 at $2.83.
